09.12.2015 • NewsElaine BurridgeRochecancer

Roche Agrees Cancer Partnership with SQZ Biotech

Roche and SQZ Biotech are working together to develop a cell therapy platform that would empower patients’ own immune cells to fight a broad range of cancers.

SQZ’s pioneering technology is based on introducing proteins, or antigens, into patients’ B cells which will then help activate killer T cells to attack the cancer. SQZ said its novel approach, which seeks to target tumors more effectively, has the potential to overcome many of the shortcomings of current cell-based therapies.

Under the deal, the US biotech firm, a spin-out of the Massachusetts Institute of Technology (MIT), will get more than $500 million in upfront and potential clinical, regulatory and sales milestone-based payments as well as royalties on potential future products.

SQZ Biotech is backed by Polaris Venture Partners and 20/20 Healthcare Partners.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.